Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 16 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

7 recruiting

Enrollment Performance

Analytics

Phase 1

12(75.0%)

Phase 2

4(25.0%)

16Total

Phase 1(12)

Phase 2(4)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (16)

Showing 16 of 16 trials

NCT07516639Phase 1Not Yet Recruiting

First-in-Human Study of ISH0613: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Role: lead

NCT07505043Phase 1Not Yet Recruiting

First-in-Human Study of ISH0688: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics

Role: lead

NCT07076095Phase 2Not Yet Recruiting

A Phase II/III Study of IBB0979 in Combination With Topotecan Versus Topotecan in Relapsed Small Cell Lung Cancer

Role: lead

NCT06504732Phase 2Recruiting

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer

Role: lead

NCT05991583Phase 1Recruiting

A Clinical Trial to Evaluate Effect of IBB0979 in Patients With Advanced Malignant Tumors

Role: lead

NCT06292208Phase 1Recruiting

A Clinical Trial to Evaluate Effect of IBD0333 in Patients With Advanced Malignant Tumors

Role: lead

NCT06581419Phase 1Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Role: lead

NCT06719479Phase 2Not Yet Recruiting

A Clinical Trial to Evaluate Effect of IAE0972 Combined with Chemotherapy for R/M HNSCC or NPC(Note: It is Currently Phase II.).

Role: lead

NCT04934514Phase 1Unknown

Clinical Study of IAH0968 in Patients With HER2-positive Advanced Solid Tumors

Role: lead

NCT05673512Phase 2Recruiting

To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Metastatic Colorectal Cancer

Role: lead

NCT05991518Phase 1Recruiting

IAH0968 in Combination With GC for the Treatment of HER2-Positive Unresectable Advanced/Metastatic Malignant Tumors

Role: lead

NCT06223841Phase 1Recruiting

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Role: lead

NCT06255964Phase 1Not Yet Recruiting

A Study of IAP0971 in Combination With Bacillus Calmette Guerin in High Risk Non-muscular Invasive Bladder Cancer

Role: lead

NCT05396391Phase 1Unknown

A Clinical Trial to Evaluate Effect of IAP0971 in Patients With Advanced Malignant Tumors

Role: lead

NCT05396339Phase 1Unknown

A Clinical Trial to Evaluate the Effect of IAE0972 in Patients With Advanced Malignant Solid Tumors.

Role: lead

NCT04980690Phase 1Unknown

Clinical Trial of IBC0966 in Patients With Advanced Malignant Tumors

Role: lead

All 16 trials loaded